The Western New York Impact Investment Fund is an innovative, for-profit investment vehicle that supports our region’s economic resurgence. Since its launch in late 2017 the fund has placed equal emphasis on the commercial promise and social impact of its investments, with rigorous analysis of both goals in its due diligence and portfolio reviews. The fund has been recognized on a national scale as a pioneer in place-based impact investing.The firm invests in the eight counties of Western New York, which includes the cities of Buffalo and Niagara Falls, and their surrounding communities. In our first five years, the fund has made nearly 20 investments that have supported the creation of hundreds of jobs. Our investments of debt and equity have targeted formerly derelict sites in lower income communities, revitalized empty factories, supported minority founding teams and injected growth capital into projects that will meaningfully improve the lives of Western New Yorkers. Tom Quinn joined the fund as its founding CEO in August 2017 and has since been recognized as one of the top business leaders in the region. Tom spearheaded the fund’s highly successful fundraising efforts and worked to systematize its due diligence processes, which place a rigorous analytical framework around the firm’s social enterprise ideals. These efforts have led the fund to being recognized as an innovator in the field of place-based impact investment, as recognized by the October 2022 article in Forbes, “Place-based impact investing takes off in Buffalo, NY." He is known for his business acumen and collaborative nature, helping companies and people look outside of their silos to focus on the bigger picture. Mr. Quinn is a tireless supporter of his hometown and believes passionately in its budding resurgence.Mr. Quinn earned his Bachelor's of Science in Pharmacy from Duquesne University, a Catholic University in Pittsburgh, PA.

Baton Pharma is an emerging legacy/specialty pharmaceutical company championing quality prescription pharmaceuticals for patients with chronic or acute recurring conditions.Presided over a four-part strategic plan and the underpinning tactics in support of company mission to revitalize legacy and specialty pharmaceuticals for patients. Scoped and adjusted the plan as needed that included: Acquisitions, Sales, Value Add, and Expansion. Utilized extensive industry experience to drive near-term and long-term corporate objectives. Created the core team responsible for plan implementation and execution.Spearheaded a $2.5 million capital raise which established an investor base consisting of debt equity and equity support including a $100 million line of credit. Finalized acquisition targets for the company which will broaden the portfolio of marketed products in US, Canada and follow-on products in Europe.

Infonaut is a health informatics and performance management company for infection prevention and control. We organize and integrate evidence to drive infection prevention and control interventions. We enable immediate, sustained and persistent improvement resulting in better patient safety and outcomes.Developed a highly successful proof of concept for a hospital’s acquired infection prevention protocol; using the unique IT platform to build a comprehensive strategy. Addressed behavior modification via analytics, data tracking and a proprietary real-time surveillance platform. Reduced hospital acquired infections by 40% in one (1) year and realized an ROI of 639% to the healthcare system.Transformed company strategy to a successful outcomes-based results vs. a fee for service model.International 43North competition winner, infusing capital into the company allowing for proof of concept for the new business model strategy.Mission: Save lives by reducing healthcare-associated infections.

EVP, Managing Director – eSampling and Patient Adherence 4/2009 – 1/2015Forged the development strategy for an e-Sampling business including scope, business development, P&L, solution design, the software engineering group and the worldwide marketing plan. Launched plan and technology platform upgrade ahead of schedule and realized significant and immediate increases in revenues. Doubled revenue in 2011 and finished the year at 121% of target and EBITDA contribution at 158% of target. Increased 2012 revenue 120% ahead of 2011 and 107% of target; EBITDA finished 135% of annual target.The Company was sold to Merck in August, 2013 for $110 millionSenior Vice President – Commercialization (MedManage Systems, Inc., Seattle, WA) 4/2003 – 4/2009Developed and fiercely executed the commercialization strategy, scope and direction, and enabled the company to achieve sales and revenue objectives. Exceeded projections for end user adoption and retention goals, and elevated revenues from $2 million in 2004, to $15+ million in 2008.Provided analytics and revenue projections to support three (3) successful rounds of venture capital fund raising over five (5) years from multiple sources around the country, including Versant Ventures and a strategic investment from Lilly Ventures. The company was acquired under Physicians Interactive, Inc. in April of 2009 by a leading global Private Equity firm, Perseus, LLC.

GeneSoft Pharmaceuticals was an emerging biopharmaceutical company which had in-licensed a quinolone anti-infective from LG Life Sciences in Seoul, South Korea. The company was successfully sold to Genome Therapeutics for $86 million in Common stock.

The primary responsibility was to prepare this start-up biopharmaceutical company for a successful NASDAQ IPO and to commercialize its first product in a very competitive United States marketplace. Primary day to day responsibilities included building the marketing function, strategic planning, finance function, medical affairs and sales force build, training and deployment. The company completed a successful license of a Biogen, Inc. compound (Angiomax®) and had a successful NASDAQ IPO in August 2000 raising $110.5 million. The company then successfully completed another Common Stock offering totaling $44 million in May 2021 led by a then leading Investment Banker, Robertson Stephens. Angiomax® gained FDA approval in December 2000 and was successfully launched in the U.S. marketplace in January 2001. An unheard of FDA approval to commercial launch timeline. The commercial organization successfully grew from a four-person department in 2000 to an organization of over 120 people in 2002. Under my direction and leadership, the organization achieved revenue in excess of $14 million in 2001 and was on target to almost triple revenue and exceed the goal of $36 million in 2002.The Medicines Company was acquired by Novartis in 2019 for $9.9 Billion.

Developed the annual, mid-term and long-term strategies aimed at growth and profit targets; and set the backbone of the organization by creating four (4) motivated strategic business development teams. Pursued and closed M&A opportunities to expand the customer and service base that included joint venture prospects and contributed ideas to broaden the marketing strategy. Concurrently served as the Managing Director of Innovex Canada to provide leadership and direction to increase presence and drive market share in the Canadian marketCompleted the acquisition of a Canadian marketing services company which added an incremental revenue stream.Revenues in 1997, 1998 and 1999 exceeded $165 million, $205 million and $270 million, respectively. Commercial Services finished 1999 with contracted backlog in excess of $400 million.